The North America Cervical Cancer Diagnostic Market would witness market growth of 3.8% CAGR during the forecast period (2023-2029).
The female reproductive tract's cervix is where cervical cancer typically begins. It is growing increasingly common as the number of HPV-positive patients rises, and early identification and treatment are being prioritized more, which is anticipated to hasten cervical cancer diagnosis. The cervix is the connecting structure between the uterus and the vagina. It typically evolves gradually over time.
Dysplasia is the name given to the process that occurs in the cells of the cervix prior to the development of cancer in that tissue. As a result, the cervical tissue begins to develop abnormal cells. If the abnormal cells are not removed or killed over time, they may develop into cancer cells, increase, and spread more into the cervix and nearby locations. The purpose of screening for the disease is to locate precancerous abnormalities in the cervix cells so that these modifications can be treated, and the progression of cervical cancer can be halted.
Government spending on healthcare and efforts to increase public awareness of early cancer detection would help the market flourish. Infection with the HPV (Human Papillomavirus) is the most frequent cause of cervical cancer. Smoking, drinking, eating a diet low in fruits and vegetables, using birth control, and underage intercourse are additional lifestyle factors that can increase risk. Women at risk of acquiring the disease must undertake routine testing to identify the condition early, allowing the market to grow. Cervical cancer is treatable once it is discovered in an early stage.
One of the most prevalent sexually transmitted diseases (STIs) in Canada is the human papillomavirus (HPV). Numerous varieties of HPV have been found; some cause cancer, while others cause skin diseases like anogenital warts. Different health effects may result from different HPV kinds. While certain varieties can affect the hands and feet, others can affect the anogenital region and spread through vaginal, oral, or anal intercourse or by close skin-to-skin contact with an infected person. In addition, it is possible to have many HPV infections going on simultaneously. The high prevalence of cervical cancer and the HPV that can cause it are anticipated to boost demand as it is highly curable in its early stages, aiding the regional market expansion.
The US market dominated the North America Cervical Cancer Diagnostic Market by Country in 2022 and would continue to be a dominant market till 2029; thereby, achieving a market value of $2,786.6 Million by 2029. The Canada market is poised to grow at a CAGR of 6.1% during (2023 - 2029). Additionally, The Mexico market would witness a CAGR of 5.2% during (2023 - 2029).
Based on Type, the market is segmented into Pap Smear Tests, Colposcopy Tests, HPV Test, Biopsy & ECC, and Others. Based on Age Group, the market is segmented into 20 to 40 years, and Above 40 years. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Cervical Cancer Diagnostic Market is Projected to reach USD 10.2 Billion by 2029, at a CAGR of 4.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Becton, Dickinson and Company, Carl Zeiss AG, CooperSurgical, Inc. (The Cooper Companies, Inc.), DYSIS Medical, Inc., F. Hoffmann-La Roche Ltd., Hologic, Inc., Qiagen N.V., Siemens Healthineers AG (Siemens AG) and Thermo Fisher Scientific, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Type
- Pap Smear Tests
- Colposcopy Tests
- HPV Test
- Biopsy & ECC
- Others
By Age Group
- 20 to 40 years
- Above 40 years
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Becton, Dickinson and Company
- Carl Zeiss AG
- CooperSurgical, Inc. (The Cooper Companies, Inc.)
- DYSIS Medical, Inc.
- F.Hoffmann-La Roche Ltd.
- Hologic, Inc.
- Qiagen N.V.
- Siemens Healthineers AG (Siemens AG)
- Thermo Fisher Scientific, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Cervical Cancer Diagnostic Market, by Type
1.4.2 North America Cervical Cancer Diagnostic Market, by Age Group
1.4.3 North America Cervical Cancer Diagnostic Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.1.1 Partnerships, Collaborations and Agreements
3.1.2 Product Launches and Product Expansions
3.1.3 Acquisition and Mergers
3.1.4 Approvals and Trials
3.1.5 Geographical and Business Expansions
3.2 Top Winning Strategies
3.2.1 Key Leading Strategies: Percentage Distribution (2019-2023)
Chapter 4. North America Cervical Cancer Diagnostic Market by Type
4.1 North America Pap Smear Tests Market by Country
4.2 North America Colposcopy Tests Market by Country
4.3 North America HPV Test Market by Country
4.4 North America Biopsy & ECC Market by Country
4.5 North America Others Market by Country
Chapter 5. North America Cervical Cancer Diagnostic Market by Age Group
5.1 North America 20 to 40 years Market by Country
5.2 North America Above 40 years Market by Country
Chapter 6. North America Cervical Cancer Diagnostic Market by Country
6.1 US Cervical Cancer Diagnostic Market
6.1.1 US Cervical Cancer Diagnostic Market by Type
6.1.2 US Cervical Cancer Diagnostic Market by Age Group
6.2 Canada Cervical Cancer Diagnostic Market
6.2.1 Canada Cervical Cancer Diagnostic Market by Type
6.2.2 Canada Cervical Cancer Diagnostic Market by Age Group
6.3 Mexico Cervical Cancer Diagnostic Market
6.3.1 Mexico Cervical Cancer Diagnostic Market by Type
6.3.2 Mexico Cervical Cancer Diagnostic Market by Age Group
6.4 Rest of North America Cervical Cancer Diagnostic Market
6.4.1 Rest of North America Cervical Cancer Diagnostic Market by Type
6.4.2 Rest of North America Cervical Cancer Diagnostic Market by Age Group
Chapter 7. Company Profiles
7.1 Abbott Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 SWOT Analysis
7.2 Becton, Dickinson and Company
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.2.5.2 Product Launches and Product Expansions:
7.2.5.3 Acquisition and Mergers:
7.2.6 SWOT Analysis
7.3 Carl Zeiss AG
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expenses
7.4 CooperSurgical, Inc. (The Cooper Companies, Inc.)
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.5 DYSIS Medical, Inc.
7.5.1 Company Overview
7.5.2 Recent strategies and developments:
7.5.2.1 Product Launches and Product Expansions:
7.6 F. Hoffmann-La Roche Ltd.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.6.5 Recent strategies and developments:
7.6.5.1 Partnerships, Collaborations, and Agreements:
7.6.5.2 Product Launches and Product Expansions:
7.6.5.3 Acquisition and Mergers:
7.7 Hologic, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expenses
7.7.5 Recent strategies and developments:
7.7.5.1 Partnerships, Collaborations, and Agreements:
7.7.5.2 Product Launches and Product Expansions:
7.7.5.3 Geographical Expansions:
7.8 Qiagen N.V.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Partnerships, Collaborations, and Agreements:
7.8.5.2 Product Launches and Product Expansions:
7.8.5.3 Acquisition and Mergers:
7.9 Siemens Healthineers AG (Siemens AG)
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.9.4 Research & Development Expense
7.9.5 SWOT Analysis
7.10. Thermo Fisher Scientific, Inc.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expenses
7.10.5 SWOT Analysis
TABLE 1 North America Cervical Cancer Diagnostic Market, 2019 - 2022, USD Million
TABLE 2 North America Cervical Cancer Diagnostic Market, 2023 - 2029, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Cervical Cancer Diagnostic Market
TABLE 4 Product Launches And Product Expansions– Cervical Cancer Diagnostic Market
TABLE 5 Acquisition and Mergers– Cervical Cancer Diagnostic Market
TABLE 6 Approvals and trials– Cervical Cancer Diagnostic Market
TABLE 7 Geographical and Business Expansions– Cervical Cancer Diagnostic Market
TABLE 8 North America Cervical Cancer Diagnostic Market by Type, 2019 - 2022, USD Million
TABLE 9 North America Cervical Cancer Diagnostic Market by Type, 2023 - 2029, USD Million
TABLE 10 North America Pap Smear Tests Market by Country, 2019 - 2022, USD Million
TABLE 11 North America Pap Smear Tests Market by Country, 2023 - 2029, USD Million
TABLE 12 North America Colposcopy Tests Market by Country, 2019 - 2022, USD Million
TABLE 13 North America Colposcopy Tests Market by Country, 2023 - 2029, USD Million
TABLE 14 North America HPV Test Market by Country, 2019 - 2022, USD Million
TABLE 15 North America HPV Test Market by Country, 2023 - 2029, USD Million
TABLE 16 North America Biopsy & ECC Market by Country, 2019 - 2022, USD Million
TABLE 17 North America Biopsy & ECC Market by Country, 2023 - 2029, USD Million
TABLE 18 North America Others Market by Country, 2019 - 2022, USD Million
TABLE 19 North America Others Market by Country, 2023 - 2029, USD Million
TABLE 20 North America Cervical Cancer Diagnostic Market by Age Group, 2019 - 2022, USD Million
TABLE 21 North America Cervical Cancer Diagnostic Market by Age Group, 2023 - 2029, USD Million
TABLE 22 North America 20 to 40 years Market by Country, 2019 - 2022, USD Million
TABLE 23 North America 20 to 40 years Market by Country, 2023 - 2029, USD Million
TABLE 24 North America Above 40 years Market by Country, 2019 - 2022, USD Million
TABLE 25 North America Above 40 years Market by Country, 2023 - 2029, USD Million
TABLE 26 North America Cervical Cancer Diagnostic Market by Country, 2019 - 2022, USD Million
TABLE 27 North America Cervical Cancer Diagnostic Market by Country, 2023 - 2029, USD Million
TABLE 28 US Cervical Cancer Diagnostic Market, 2019 - 2022, USD Million
TABLE 29 US Cervical Cancer Diagnostic Market, 2023 - 2029, USD Million
TABLE 30 US Cervical Cancer Diagnostic Market by Type, 2019 - 2022, USD Million
TABLE 31 US Cervical Cancer Diagnostic Market by Type, 2023 - 2029, USD Million
TABLE 32 US Cervical Cancer Diagnostic Market by Age Group, 2019 - 2022, USD Million
TABLE 33 US Cervical Cancer Diagnostic Market by Age Group, 2023 - 2029, USD Million
TABLE 34 Canada Cervical Cancer Diagnostic Market, 2019 - 2022, USD Million
TABLE 35 Canada Cervical Cancer Diagnostic Market, 2023 - 2029, USD Million
TABLE 36 Canada Cervical Cancer Diagnostic Market by Type, 2019 - 2022, USD Million
TABLE 37 Canada Cervical Cancer Diagnostic Market by Type, 2023 - 2029, USD Million
TABLE 38 Canada Cervical Cancer Diagnostic Market by Age Group, 2019 - 2022, USD Million
TABLE 39 Canada Cervical Cancer Diagnostic Market by Age Group, 2023 - 2029, USD Million
TABLE 40 Mexico Cervical Cancer Diagnostic Market, 2019 - 2022, USD Million
TABLE 41 Mexico Cervical Cancer Diagnostic Market, 2023 - 2029, USD Million
TABLE 42 Mexico Cervical Cancer Diagnostic Market by Type, 2019 - 2022, USD Million
TABLE 43 Mexico Cervical Cancer Diagnostic Market by Type, 2023 - 2029, USD Million
TABLE 44 Mexico Cervical Cancer Diagnostic Market by Age Group, 2019 - 2022, USD Million
TABLE 45 Mexico Cervical Cancer Diagnostic Market by Age Group, 2023 - 2029, USD Million
TABLE 46 Rest of North America Cervical Cancer Diagnostic Market, 2019 - 2022, USD Million
TABLE 47 Rest of North America Cervical Cancer Diagnostic Market, 2023 - 2029, USD Million
TABLE 48 Rest of North America Cervical Cancer Diagnostic Market by Type, 2019 - 2022, USD Million
TABLE 49 Rest of North America Cervical Cancer Diagnostic Market by Type, 2023 - 2029, USD Million
TABLE 50 Rest of North America Cervical Cancer Diagnostic Market by Age Group, 2019 - 2022, USD Million
TABLE 51 Rest of North America Cervical Cancer Diagnostic Market by Age Group, 2023 - 2029, USD Million
TABLE 52 Key Information – Abbott Laboratories
TABLE 53 Key information – Becton, Dickinson and Company
TABLE 54 key Information – Carl Zeiss AG
TABLE 55 Key Information – CooperSurgical, Inc.
TABLE 56 Key information – DYSIS Medical, Inc.
TABLE 57 KEY INFORMATION – F. Hoffmann-La Roche Ltd.
TABLE 58 Key Information – Hologic, Inc.
TABLE 59 Key Information – Qiagen N.V.
TABLE 60 Key Information – Siemens Healthineers AG
TABLE 61 Key Information – Thermo Fisher Scientific, Inc.
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 4 North America Cervical Cancer Diagnostic Market share by Type, 2022
FIG 5 North America Cervical Cancer Diagnostic Market share by Type, 2029
FIG 6 North America Cervical Cancer Diagnostic Market by Type, 2019 - 2029, USD Million
FIG 7 North America Cervical Cancer Diagnostic Market share by Age Group, 2022
FIG 8 North America Cervical Cancer Diagnostic Market share by Age Group, 2029
FIG 9 North America Cervical Cancer Diagnostic Market by Age Group, 2019 - 2029, USD Million
FIG 10 North America Cervical Cancer Diagnostic Market share by Country, 2022
FIG 11 North America Cervical Cancer Diagnostic Market share by Country, 2029
FIG 12 North America Cervical Cancer Diagnostic Market by Country, 2019 - 2029, USD Million
FIG 13 Swot analysis: Abbott laboratories
FIG 14 Recent strategies and developments: Becton, Dickinson and Company
FIG 15 Swot analysis: Becton, Dickinson and company
FIG 16 Recent strategies and developments: F. Hoffmann-La Roche Ltd.
FIG 17 Recent strategies and developments: Hologic, Inc.
FIG 18 Recent strategies and developments: Qiagen N.V.
FIG 19 Swot analysis: Siemens AG
FIG 20 Swot analysis: thermo fisher scientific, inc.